wescobrk Posted September 13, 2020 Share Posted September 13, 2020 Gilead is buying Immunomedcis for $88 a share in cash. Depending on what the stock starts trading at tomorrow, this could be an interesting risk arb deal. Anyone on the board that has knowledge in this sector as far as any regulatory agencies risk that might kill the deal? I don't see high risk of the deal not going through. The FDA approved trodelvy in April and Gilead has made similar acquisitions in the past. Link to comment Share on other sites More sharing options...
Create an account or sign in to comment
You need to be a member in order to leave a comment
Create an account
Sign up for a new account in our community. It's easy!Register a new account
Already have an account? Sign in here.Sign In Now